Mr. Dean Burns reports

OCUMETICS TECHNOLOGY ANNOUNCES AMENDMENT TO BROKERED LIFE OFFERING LED BY CENTURION ONE CAPITAL

Further to Ocumetics Technology Corp.'s previously announced (Nov. 25, 2025) brokered private placement on a best-efforts basis led by Centurion One Capital Corp. (the lead agent), the corporation has amended the terms of the offering.

Pursuant to the amended terms, up to 4,166,666 units of the corporation will now be issued at an amended issue price of 60 cents per unit for aggregate gross proceeds of up to $2.5-million. Each unit shall consist of one common share in the capital of the corporation and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share of the corporation at an exercise price of 75 cents per warrant share at any time for a period of three years following the closing date (as defined herein).

In addition, the corporation will now grant the lead agent an option to sell up to an additional 625,000 units at the amended issue price for additional gross proceeds of up to $375,000 on the same terms and conditions as set out herein. The agent's option is exercisable in whole or in part at any time up to two business days prior to the closing date.

The gross proceeds of the offering are expected to be used to finance the corporation's first-in-human clinical trials, for continuing research and development, and for general corporate purposes. Although the corporation intends to use the proceeds of the offering as described above, the actual allocation of proceeds may vary from the uses set out above, depending upon future operations, events or opportunities.

The units will be offered for sale: (i) by way of private placement pursuant to the listed issuer financing exemption under Section 5A.2 of National Instrument 45-106, Prospectus Exemptions, as amended and supplemented by Coordinated Blanket Order 45-935, Exemptions from Certain Conditions of the Listed Issuer Financing Exemption, in British Columbia, Alberta and Ontario; (ii) in the United States pursuant to an exemption from the registration requirements of the U.S. Securities Act of 1933, as amended, and applicable U.S. state securities laws, and (iii) in jurisdictions outside of Canada and the United States as mutually agreed to by the corporation and the lead agent, provided it is understood that no prospectus filing, registration or comparable obligation arises in such other jurisdiction. The securities issued under the listed issuer financing exemption will not be subject to a statutory hold period pursuant to applicable Canadian securities laws.

There is an amended and restated offering document related to this offering that can be accessed under the corporation's profile on SEDAR+ and on the corporation's website. Prospective investors should read this offering document before making an investment decision.

The offering is expected to close on or around Dec. 29, 2025, or such other date as agreed upon between the corporation and the lead agent and is subject to certain conditions, including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Venture Exchange.

It is anticipated that certain insiders of the corporation, the lead agent and certain affiliates may acquire units in the offering. Any participation by insiders in the offering will constitute a related party transaction as defined under Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions. The corporation expects such participation will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the units subscribed for by the insiders nor the consideration for the units paid by such insiders is expected to exceed 25 per cent of the corporation's market capitalization.

About Ocumetics Technology Corp.

Ocumetics Technology is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

We seek Safe Harbor.